Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 13 (5), 483-497

Management of Antibiotic-Resistant Helicobacter pylori Infection: Perspectives From Vietnam

Affiliations
Review

Management of Antibiotic-Resistant Helicobacter pylori Infection: Perspectives From Vietnam

Vu Van Khien et al. Gut Liver.

Abstract

Antibiotic resistance is the most important factor leading to the failure of eradication regimens. This review focuses on the prevalence of Helicobacter pylori primary and secondary resistance to clarithromycin, metronidazole, amoxicillin, levofloxacin, tetracycline, and multidrug in Vietnam. We searched the PubMed, EMBASE, Vietnamese National Knowledge Infrastructure, and Vietnamese Biomedical databases from January 2000 to December 2016. The search terms included the following: H. pylori infection, antibiotic (including clarithromycin, metronidazole, amoxicillin, levofloxacin, tetracycline, and multidrug) resistance in Vietnam. The data were summarized in an extraction table and analyzed manually. Finally, Excel 2007 software was used to create charts. Ten studies (three studies in English and seven in Vietnamese) were included in this review. A total of 308, 412, 523, 408, 399, and 268 H. pylori strains were included in this review to evaluate the prevalence of H. pylori primary resistance to amoxicillin, clarithromycin, metronidazole, levofloxacin, tetracycline, and multidrug resistance, respectively. Overall, the primary resistance rates of amoxicillin, clarithromycin, metronidazole, levofloxacin, tetracycline, and multidrug resistance were 15.0%, 34.1%, 69.4%, 27.9%, 17.9% and 48.8%, respectively. Secondary resistance rates of amoxicillin, clarithromycin, metronidazole, levofloxacin, tetracycline, and multidrug resistance were 9.5%, 74.9%, 61.5%, 45.7%, 23.5% and 62.3%, respectively. In Vietnam, primary and secondary resistance to H. pylori is increasing over time and affects the effectiveness of H. pylori eradication.

Keywords: Amoxicillin; Bismuth; Clarithromycin; Helicobacter pylori; Metronidazole.

Conflict of interest statement

CONFLICTS OF INTEREST

No potential conflict of interest relevant to this article was reported.

Figures

Fig. 1
Fig. 1
Map of Vietnam with three different regions: North, Central, and South. Note: North Vietnam includes northwestern, northeast and Red River Delta areas. Central Vietnam includes north central coast, south central coast and central highlands. South Vietnam includes southeastern and Mekong River Delta areas. Reprinted with the permission of Nations Online Project.
Fig. 2
Fig. 2
Average rate of primary resistance with Helicobacter pylori in Vietnam from 2001 to 2016.
Fig. 3
Fig. 3
Multidrug resistance patterns of Helicobacter pylori in Vietnam. C+M, clarithromycin+metronidazole; C+L, clarithromycin+levofloxacin; C+T, clarithromycin+tetracycline; M+L, metronidazole+levofloxacin; M+T, metronidazole+tetracycline; L+T, levofloxacin+ tetracycline.

Similar articles

See all similar articles

References

    1. Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet. 1984;1:1311–1315. doi: 10.1016/S0140-6736(84)91816-6. - DOI - PubMed
    1. Blaser MJ, Atherton JC. Helicobacter pylori persistence: biology and disease. J Clin Invest. 2004;113:321–333. doi: 10.1172/JCI20925. - DOI - PMC - PubMed
    1. Vakil N, Megraud F. Eradication therapy for Helicobacter pylori. Gastroenterology. 2007;133:985–1001. doi: 10.1053/j.gastro.2007.07.008. - DOI - PubMed
    1. Fukase K, Kato M, Kikuchi S, et al. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet. 2008;372:392–397. doi: 10.1016/S0140-6736(08)61159-9. - DOI - PubMed
    1. Dinis-Ribeiro M, Areia M, de Vries AC, et al. Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED) Endoscopy. 2012;44:74–94. doi: 10.1055/s-0031-1291491. - DOI - PMC - PubMed

LinkOut - more resources

Feedback